[1] |
Hanouneh IA,Macaron C,Lopez R, et al. Rate of tumor growth predicts recurrence of hepatocellular carcinoma after liver transplantation in patients beyond Milan or UCSF criteria[J]. Transplant Proc, 2011, 43(10): 3813-3818.
|
[2] |
Lei J,Yan L. Comparison between living donor liver transplantation recipients who met the Milan and UCSF criteria after successful downstaging therapies[J]. J Gastrointest Surg, 2012, 16(11): 2120-2125.
|
[3] |
Macaron C,Hanouneh IA,Lopez R, et al. Total tumor volume predicts recurrence of hepatocellular carcinoma after liver transplantation in patients beyond Milan or UCSF criteria[J]. Transplant Proc, 2010, 42(10): 4585-4592.
|
[4] |
钱建平,李湘竑,朱碧丽, 等.肝癌肝移植术后肿瘤复发的防治策略[J].器官移植, 2012, 3(5): 295-300.
|
[5] |
Chen GH. Liver transplantation in China: retrospect and prospect[J]. Chin Med J, 2009, 122(19): 2229-2230.
|
[6] |
Fan J,Yang GS,Fu ZR, et al. Liver transplantation outcomes in 1,078 hepatocellular carcinoma patients: a multi-center experience in Shanghai, China[J]. J Cancer Res Clin Oncol, 2009, 135(10): 1403-1412.
|
[7] |
Lei J,Yan L. Outcome comparisons among the Hangzhou, Chengdu, and UCSF criteria for hepatocellular carcinoma liver transplantation after successful downstaging therapies[J]. J Gastrointest Surg, 2013, 17(6): 1116-1122.
|
[8] |
Ahn SY,Lee HS,Kweon YO, et al. Sustained remission over 36 months of advanced hepatocellular carcinoma after short-term sorafenib therapy[J]. Dig Dis Sci, 2013, 58(5): 1428-1432.
|
[9] |
Chung YH,Han G,Yoon JH, et al. Interim analysis of START: study in Asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial[J]. Int J Cancer, 2013, 132(10): 2448-2458.
|
[10] |
D'Angelo S,Secondulfo M,De Cristofano R, et al. Selection and management of hepatocellular carcinoma patients with sorafenib: recommendations and opinions from an Italian liver unit[J]. Future Oncol, 2013, 9(4): 485-491.
|
[11] |
Song P,Gao J,Inagaki Y, et al. Biomarkers: evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and China[J]. Liver Cancer, 2013, 2(1): 31-39.
|
[12] |
Song PP. Standardizing management of hepatocellular carcinoma in China: devising evidence-based clinical practice guidelines[J]. Biosci Trends, 2013, 7(5): 250-252.
|
[13] |
Davis E,Wiesner R,Valdecasas J, et al. Treatment of recurrent hepatocellular carcinoma after liver transplantation[J]. Liver Transpl, 2011, 17(Suppl 2): S162-S166.
|
[14] |
Moroni M,Zanlorenzi L. Complete regression following sorafenib in unresectable, locally advanced hepatocellular carcinoma[J]. Future Oncol, 2013, 9(8): 1231-1237.
|
[15] |
Palmer DH,Hussain SA,Smith AJ, et al. Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United Kingdom[J]. Br J Cancer, 2013, 109(4): 888-890.
|
[16] |
Waghray A,Balci B,El-Gazzaz G, et al. Safety and efficacy of sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation[J]. Clin Transplant, 2013, 27(4): 555-561.
|
[17] |
Saab S,McTigue M,Finn RS, et al. Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy[J]. Exp Clin Transplant, 2010, 8(4): 307-313.
|
[18] |
Yan J,Tan C,Gu F, et al. Sorafenib delays recurrence and metastasis after liver transplantation in a rat model of hepatocellular carcinoma with high expression of phosphorylated extracellular signal-regulated kinase[J]. Liver Transpl, 2013, 19(5): 507-520.
|